作者
Morteza Zarrabi, Mohammad Amin Shahrbaf, Masoumeh Nouri, Faezeh Shekari, Seyedeh-Esmat Hosseini, Seyed-Mohammad Reza Hashemian, Rasoul Aliannejad, Hamidreza Jamaati, Naghmeh Khavandgar, Hediyeh Alemi, Hoda Madani, Abdoreza Nazari, Azadeh Amini, Seyedeh Nafiseh Hassani, Fatemeh Abbasi, Neda Jarooghi, Nasrin Fallah, Leila Taghiyar, Meysam Ganjibakhsh, Ensiyeh Hajizadeh-Saffar, Massoud Vosough, Hossein Baharvand
发表日期
2023/6/26
期刊
Stem Cell Research & Therapy
卷号
14
期号
1
页码范围
169
出版商
BioMed Central
简介
Background and aims
The main causes of death in patients with severe Coronavirus disease-2019 (COVID-19) are acute respiratory distress syndrome (ARDS) and multiorgan failure caused by a severe inflammatory cascade. Novel treatment strategies, such as stem-cell-based therapy and their derivatives can be used to relieve inflammation in these cases. In this study, we aimed to evaluate the safety and efficacy of therapy using mesenchymal stromal cells (MSCs) and their derived extracellular vesicles in COVID-19 patients.
Materials and methods
COVID-19 patients with ARDS were included in this study and allocated into two study and control groups using block randomization. While all patients received recommended treatment based on guidelines from the national advisory committee for COVID-19 pandemic, the two intervention groups received two consecutive injections of MSCs (100 × 106 cells) or one …
学术搜索中的文章
M Zarrabi, MA Shahrbaf, M Nouri, F Shekari… - Stem Cell Research & Therapy, 2023